Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (1): 61-62.
Previous Articles Next Articles
YUAN Qianqian1, TANG Kun2,*
Received:2018-06-11
Revised:2019-02-18
Online:2019-01-20
Published:2019-02-18
CLC Number:
YUAN Qianqian, TANG Kun. One Case of Erythroderma Induced by Teicoplanin for Injection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 61-62.
Add to citation manager EndNote|Ris|BibTeX
| [1] Nosbaum A, Nicolas J F.Glycopeptide-induced cutaneous adverse reaction[J]. Annales de dermatologie et de venereologie, 2010,137(5):341-342. [2] Ebrahimpour S, Mohammadi M, Gholami K.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) with Teicoplanin: A Case Report[J]. Drug Saf, 2017,4(1):1-4. [3] Asero R.Teicoplanin-induced anaphylaxis[J]. Allergy, 2006,61(11):1370. [4] Yang L P, Zhang A L,Wang D D,et al.Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin[J]. Journal of Clinical Pharmacy and Therapeutics, 2014,39(4):442-445. [5] 张湘衡,陈忠平.抗癫痫新药左乙拉西坦[J]. 中国神经肿瘤杂志, 2010,8(2):120-123. [6] 应义,崔,张慧.抗癫痫药物研究现状与新进展[J]. 中国药业, 2012,21(20):111-112. [7] 包振宇,邹先彪.重症药疹的研究进展[J]. 实用皮肤病学杂志, 2015,8(2):112-118. [8] 金菊花. 剥脱性皮炎282例临床分析[D]. 吉林大学硕士学位论文, 2011:3. [9] Akhyani M, Ghodsi Z S, Toosi S, et al.Erythroderma: a clinical study of 97 cases[J]. BMC Dermatology, 2005, 5:5. [10] Sheen Y S, Chu C Y, Wang S H, et al.Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan[J]. J Dermatolog Treat, 2009, 20(6): 340. [11] 刘秀琼,许娟.去甲万古霉素致严重剥脱性皮炎1例[J]. 中国执业药师, 2014,11(5):53-54. [12] 李奎宝,那开宪.去甲万古霉素致严重剥脱性皮炎一例[J]. 首都医药, 2006,13(10):49. [13] 吴琳,倪穗琴.万古霉素致剥脱性皮炎1例[J]. 广东药学, 2004,14(6):49. [14] Paul C, Janier M, Carlet J, et al.Erythroderma induced by teicoplanin[J]. Ann Dermatol Venereol, 1992,119(9):667-669. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
